BioCentury
ARTICLE | Clinical News

Lifitegrast: Phase III started

January 14, 2013 8:00 AM UTC

SARcode began the double-blind, placebo-controlled, U.S. Phase III OPUS-2 trial to evaluate twice-daily 5% lifitegrast for 12 weeks in about 700 patients with dry eye disease who have used artificial ...